Merit Medical Systems Logo
US5898891040
882361
MMSI

Merit Medical Systems

Forecast

The analysts' average price target is €98.43 (+27.83%). The median is €96.15 (+24.87%).

Buy
  12
Hold
  3
Sell
  1

Discussions in the community

There is no discussion about this asset yet.

Start discussion

  • Lynne N. Ward sells 5,000 Merit Medical Systems shares, reducing direct stake by 39%

    Director Lynne N. Ward executed an open-market sale of 5,000 Merit Medical Systems shares on May 7 for about $313,000, cutting her direct holdings from 12,809 to 7,809 shares. The sale occurred amid a share decline to a 52-week low and investor concerns about macroeconomic headwinds, higher tariffs and decelerating revenue growth. Ward's remaining position suggests the disposition may have been personal rather than a full loss of confidence in the company. » More on finance.yahoo.com


  • Merit Medical Systems hits new 52-week low at $60.50

    Merit Medical Systems shares fell to a new 52-week low of $60.50, losing 7.09% last week and down about 34.7% year-to-date. Ten analysts have cut their earnings estimates despite the company having a Piotroski score of 9. Merit reported better-than-expected results for Q1 2026 and slightly raised its revenue outlook, while analysts adjusted price targets differently (Needham $90, BofA $80). » More on de.investing.com


  • Merit Medical beats Q1 2026 revenue and earnings forecasts

    Merit Medical reported Q1 2026 EPS of $0.86 (expectation $0.83) and revenue of $381.9 million (expectation $377.81 million), representing 7% year-over-year revenue growth. The non-GAAP operating margin was 19.7%, the highest first-quarter level in company history. The stock rose 5.24% after hours. For the next fiscal year the company expects EPS between $0.98 and $1.17 but cites risks from tariffs, OEM inventory drawdowns and geopolitical tensions. » More on de.investing.com


  • Merit Medical hits 52-week low at $66.33

    The stock of Merit Medical Systems fell to a 52-week low of $66.33, well below this year’s high of $100.19; over 12 months the stock lost 29.92%. Eight analysts recently lowered their earnings estimates, yet the company shows strong financial health and a P/E ratio of 31.18 according to the data. Quarterly results are due in two days; analysts’ price targets range from $78 to $122. Merit also reported the acquisition of View Point Medical for $140 million and an exclusive distribution agreement with Medtronic for the ViaVerte system, prompting analysts to update their targets differently. » More on de.investing.com


  • Merit Medical buys View Point Medical for $140 million

    Merit Medical is acquiring View Point Medical as a 100% subsidiary in a transaction with a total value of approximately $140 million. Merit paid $90 million in cash at closing; two additional payments of $25 million each will follow on the first two anniversaries. The acquisition expands Merit’s therapeutic oncology portfolio through the FDA‑cleared OneMark Detection Imaging System and is expected to contribute about $2–4 million in revenue in 2026, rising to $14–16 million in 2027. For 2026, Merit expects non‑GAAP earnings dilution of roughly $0.05 per share, but the acquisition is expected to be accretive over the long term; Piper Sandler advised financially and Baker & McKenzie provided legal counsel. » More on de.investing.com

Financials

In the last quarter, Merit Medical Systems had revenue of €367.48m and net profit of €37.35m

(EUR) September 2026
YoY
Revenue 367.48m 12.23%
Gross profit 177.13m 11.45%
Net profit 37.35m 57.94%
EBITDA 83.84m 23.70%

Fundamentals

Metric Value
Market capitalization
€4.61bn
Number of shares
59.92m
52-week high/low
€86.44 - €54.44
Dividends No
Beta
0.55
P/E ratio
31.35
PEG ratio
0.93
P/B ratio
2.89
P/S ratio
3.14

Company profile

Merit Medical Systems, Inc. designs, develops, manufactures, and markets single-use medical products for interventional, diagnostic, and therapeutic procedures, primarily in cardiology, radiology, oncology, critical care, and endoscopy. The company operates in two segments, Cardiovascular and Endoscopy. It provides peripheral intervention products for the diagnosis and treatment of diseases in peripheral vessels and organs; and cardiac intervention products, such as access, angiography, electrophysiology and cardiac rhythm management, fluid management, hemodynamic monitoring, hemostasis, and intervention to treat various heart conditions. The company also offers custom procedural solutions that include critical care products, disinfection protection systems, syringes, manifold kits, and trays and packs; coated tubes and wires; and sensor components for microelectromechanical systems. In addition, it provides pulmonary products that consist of laser-cut tracheobronchial stents, over-the-wire and direct visualization delivery systems, and dilation balloons to endoscopically dilate strictures; gastroenterology products; and kits and accessories for endoscopy and bronchoscopy procedures. The company sells its products to hospitals and alternate site-based physicians, technicians, and nurses through direct sales force, distributors, original equipment manufacturer partners, or custom procedure tray manufacturers in the United States and internationally. Merit Medical Systems, Inc. was incorporated in 1987 and is headquartered in South Jordan, Utah.

Name
Merit Medical Systems
CEO
Martha Goldberg Aronson
Headquarters South Jordan, ut
USA
Website
Sector
Consumer Discretionary
Industry
Household Durables
IPO
14/05/1990
Employees 7,500

Ticker symbols

Exchange Symbol
NASDAQ
MMSI
Frankfurt
MM3.F
DĂĽsseldorf
MM3.DU
MĂĽnchen
MM3.MU
🍪

Parqet  uses cookies. Learn more